Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia

Psychiatric Genetics

Volumn 14, Issue 4, 2004, Pages 209-213

  Matsumoto, Chima ^a   Ohmori, Osamu ^a,b   Shinkai, Takahiro ^a   Hori, Hiroko ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Wakato Hospital   (Japan)

Author keywords

Cytochrome P450 1A2 (CYP1A2); Polymorphism; Schizophrenia; Tardive dyskinesia

Indexed keywords

BROMPERIDOL; CHLORPROMAZINE; CLOCAPRAMINE; CLOSPIPRAMINE; CYTOCHROME P450 1A2; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PERICIAZINE; PIPAMPERONE; SULPIRIDE; SULTOPRIDE; THIORIDAZINE; ZOTEPINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN CELL; JAPAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA; SMOKING; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; BASE SEQUENCE; CYTOCHROME P-450 CYP1A2; DNA PRIMERS; DYSKINESIAS; FEMALE; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SMOKING;

EID: 11144227365     PISSN: 09558829     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041444-200412000-00008     Document Type: Article

References (22)

1. Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, et al. (2000). A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 5:410-417.
2. Brosen K, Gram LF (1989). Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36:537-547.
3. Casey DE (2000). Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry 61 (suppl 4):5-9.
4. Dahl ML (2002). Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 41:453-470.
5. Devlin B, Risch N (1995). A comparison of linkage disequilibrium measures for fine-scale mapping, Genomics 29:311-322.
6. Ellingrod VL, Schultz SK, Arndt S (2000). Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score. Psychiatr Genet 10:9-11.
7. Gerlach J, Casey DE (1988). Tardive dyskinesia. Acta Psychiatr Scand 77:369-378.
8. Guy W (1976). Abnormal involuntary movement scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology, US DWEW publication, revised. Washington, DC: Department Health, Education and Welfare; pp. 534-537.
9. Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K, et al. (1998). Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 32:101-106.
10. Lam LCW, Garcia-Barcelo MM, Ungvari GS, Tang WK, Lam VKL, Kwong SL, et al. (2001). Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiatry 34: 238-241.
11. Lewontin RC (1964). The interaction of selection and linkage. I. General considerations; heterotic models. Genetics 49:49-67.
12. Miller DD, Kelly MW, Perry PJ, Coryell WH (1990). The influence of cigarette smoking on haloperidol pharmacokinetics. Biol Psychiatry 28:529-531.
13. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T (1999). Genetic polymorphisms in the 5′-flanking region of human CYP1A2 gene: effects on the CYP1A2 inducibility in humans. J Biochem 125:803-808.
14. Ohmori O, Suzuki T, Kojima H, Shinkai T, Tarao T, Mita T, Abe K (1998). Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 32:107-113.
15. Okey AB (1990). Enzyme induction in the cytochrome P-450 system. Pharmacol Ther 45:241-298.
16. Sachse C, Bröckmoller J, Bauer S, Roots I (1997). Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295.
17. Sachse C, Brockmoller J, Bauer S, Roots I (1999). Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449.
18. Schooler NR, Kane JM (1982). Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39:486-487.
19. Schulze TG, Schumacher J, Muller DJ, Krauss H, Alfter D, Maroldt A, et al. (2001). Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 8:498-501.
20. Sham PC, Curtis D (1995). Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 59:97-105.
21. Terwilliger JD, Ott J (1994). Handbook of Human Genetic Linkage. Baltimore, MD: Johns Hopkins University Press.
22. Toru M (1983.) Seishinbunnretsubyo no yakuri [Pharmacology in Schizophrenia]. Tokyo: Chu-gai Igakusha.